Alliance Pharma (LON:APH) expects sales momentum to build further after revenues rose by nearly 7% in the first half of 2015.
The prescription drug supplier benefited from a strong contribution from the recently acquired eye treatment Macushield, while one of its strongest products, bladder cancer cream ImmuCyst, will be back on sale again from the final quarter.
Sales in the half year to June were £22.8mln (£21.4mln), while profits edged up to £5.5mln (£5.4mln).
Macushield, a capsule to combat age related macular degeneration and a common cause of eyesight loss in the elderly, chipped in revenues of £1.4mln for the five months it was included.
Elsewhere, eczema cream Hyrdromol increased sales by 11% while baby powders business Ashton & Parsons saw a 19% jump after heavier promotion.
In the second half, ImmuCyst will contribute again as manufacturer Sanofi has sorted its production issues and Alliance is hopeful demand will recover quickly following a three-year absence.
Alliance has also licensed in Diclectin from Canadian firm Duchesnay.
Diclectin treats nausea and vomiting during pregnancy, something that is not available currently in the UK and Alliance expects a lot of interest when it is launched next year.
There will be costs gearing up for that launch, but Alliance expects to meet market expectations for the full year.
The interim dividend rises by 10% to 0.366p.